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Abstract. In the era of patient-centered medicine, shared decision-making (SDM) – in which healthcare professionals and
patients exchange information and preferences and jointly reach a decision – has emerged as the gold standard model for
the provision of formal healthcare. Indeed, in many geographical settings, patients are frequently invited to participate in
choices concerning the design and delivery of their medical management. From a clinical perspective, benefits of this type of
patient involvement encompass, for example, enhanced treatment satisfaction, improved medical compliance, better health
outcomes, and maintained or promoted quality of life. Yet, although the theory and enactment of SDM in healthcare are
well-described in the literature [1–3], comparatively less attention has been devoted to contextualizing questions relating
to if, when, and how to include patients in decisions within medical research. In this context, patient involvement would
be expected to be potentially relevant for and applicable to a wide range of activities and processes, from the identification
of research priorities and development of grant applications, to the design of patient information and consent procedures,
formulation of interventions, identification and recruitment of study sample populations, feasibility of a clinical trial, identifi-
cation, selection, and specification of endpoints and outcomes in clinical trials and observational studies, data collection and
analysis, and dissemination of results. To this end, 45 clinicians, healthcare professionals, researchers, patients, caregivers,
and representatives from regulatory authorities and pharmaceutical companies from 15 different countries met to discuss the
level of involvement of patients with neuromuscular diseases, specifically in the following settings of medical research for
neuromuscular diseases: i) registries and biobanks; ii) clinical trials; and iii) regulatory processes. In this report, we present
summaries of the talks that were given during the workshop, as well as discussion outcomes from the three topic areas listed
above.
Keywords: Patient participation, biomedical research, quality of life, consensus
BACKGROUND
Involving patients in research has long been rec-
ognized as a key issue for many rare disorders, and
patient contributions have been manifold: from (polit-
ical) agenda setting, building networks, and sharing
knowledge, to engaging with industry or, albeit to
a lesser extent, actively participating in the plan-
ning and conduct of biomedical research (community
engaged research) [4–9].
Shared Decision Making (SDM) is a model of
communication between a health professional and a
patient about the options of prevention, screening,
diagnostic tests and treatment, including the option
of not intervening; an approach where clinicians and
patients share the best available evidence when faced
with the task of making decisions, and where patients
are supported to consider options and to achieve
informed preferences [10, 11] in contrast to a sim-
ple informed consent [12]. The goals of SDM are:
better-informed patients, more confidence in and sat-
isfaction about the treatment and more compliance.
The model consists of three steps: choice talk, option
talk and decision talk. During the choice talk it is
decided whether or not the patient will actively partic-
ipate in the decision-making process: not all patients
want this or are able to do so. In the option talk, the
professional presents all options in a neutral fashion
without indicating his or her own preference. Dur-
ing the decision talk, professional and patient decide
about the options and arrange follow-up [13].
We refer to the terminology defined by the National
Institute for Health Research (UK) regarding the use
of following terms [14]:
Patient and public involvement is the develop-
ment of partnerships between patients, carers or other
members of public and researchers. Such partner-
ships are made in order to influence what research
is done, how, and what happens to the results.
Patient and public engagement is the sharing of
information and knowledge about research by pro-
fessionals, such as at open days, science festivals or
through newspapers or other media.
Patient and public participation is the recruitment
of patients or others to take part in clinical trials or
other research studies.
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GOALS OF THE WORKSHOP
For years, ENMC has implemented a strict policy
[15] to include all stakeholders among the work-
shops’ participants, in particular patients affected by
neuromuscular diseases (NMD) and their representa-
tives from patient organisations and support groups.
ENMC itself is funded and governed by the NMD
patient organisations of different European countries
and has decided to contribute in applying the con-
cept of SDM to wider areas of NMD-healthcare and
–research than in the dual communication between
professional and patient, by organizing a special
workshop in occasion of ENMC’s 25th anniver-
sary. The workshop was attended by 45 participants
from 15 different countries: Belgium, Denmark, Fin-
land, France, Germany, Greece, Hungary, Italy, The
Netherlands, Poland, Spain, Sweden, Switzerland,
UK and the USA. This group represented a wide
range of experts: patients and parents, representa-
tives from NMD organisations, clinicians, health
care professionals, researchers, societal and policy
researchers, psychologists, ethicists, representatives
from regulatory authorities and pharmaceutical
companies.
This special ENMC workshop aimed at imple-
menting patient involvement in the field of NMD
by taking on board the model of SDM; explore
opportunities and improve the level and quality of
patient involvement in areas that are closely related
to disease, care and treatment, where decisions are
traditionally made by health care professionals, as
well as in areas related to research settings:
1. psycho-social support of families going through
the processes of screening and diagnosis
2. transition from child, to adolescent to adult
patient
3. research that has major impact on daily life
(nutrition, pain, fatigue)
4. registries and biobanks
5. clinical trial design
6. regulatory and consenting processes
In the first part of the workshop the concepts of
SDM and of patient involvement were introduced. In
the second part, after presenting the six topics, patient
organizations, professionals, industry, and regulators
addressed the raised issues in small group discus-
sions. The three SDM steps (option talk, choice talk,
decision talk) were applied to structure the discus-
sions in a way that examines i) the interest of the
patients in increasing their engagement in a particu-
lar field; ii) the state of the art of patient involvement
in that field (good examples, illustrated in the plenary
talks) and opportunities to increase it, identifying
challenges and barriers; iii) the consensus of the
stakeholder community as to which improvements
are wished for the near future. Finally, the conclusions
obtained in each discussion group were presented
and summarized in a table of recommendations (see
Table 1).
This workshop report will focus on the discussions
and outcomes related to research settings, e.g. topics
4, 5 and 6. The discussions and outcomes of the qual-
ity of life-topics and health care, e.g. topics 1, 2 and
3 will be reported elsewhere; only a brief overview
of the outcomes of this part is reported here for the
sake of completeness.
INTRODUCTORY TALKS
Guus Schrijvers opened the workshop illustrating
the traditional SDM concept. He highlighted that
proper allocation of time for discussion and compre-
hension of the health problem by all stakeholders is
a key factor for its success. He provided his personal
experience in this field and concluded by addressing
the potential of improving the level of patient involve-
ment from the dual conversation with the doctor to
the levels of political decisions and of definition of
research priorities.
Ingeborg Meijer introduced another working
model to describe the level of patient’s involvement
in the decision processes that relate to health, called
“the ladder of participation” [16] (Fig. 1). The par-
ticipation ladder is about power structures in society
and how they interact. Specifically, it is a guide to
seeing who has power when important decisions are
being made.
The actions represented by the ladder’s steps not
necessarily refer to individual decisions on health
care alone, but they could easily be transposed and
explored regarding patient involvement in research.
Meijer pointed out the need for a change in culture
in many medical research disciplines in order to suc-
ceed in the empowerment of patients, their families
and advocates, but this change should be adopted also
by researchers, doctors, and all other professionals.
She highlighted the timeliness of addressing this issue
in the NMD field. In fact, in an era where evidence-
based medicine does not provide the answers yet and
the change from ‘one size fits all’ to personalised
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Table 1
Recommendations of the ENMC workshop study group
Educational changes (Patients
organisations, institutions)




– The consequences in donating
samples or clinical data to
biobanks and registries should
be fully understood by
participating patients: possible
long times before research
delivers results, need of
actualized data in registries,
worldwide use of samples and
data
– The consent form should be
updated to accommodate
modern techniques applied to
cell lines and biopsies, and
written together with patient
organisations to ensure
understanding
– The position for patient organisations
in the ladder of participation should be
at a top level (collaboration and/or
control)
– Patients who donate data or samples
are to be seen as partners in research
and should be aware of this role
– Use of samples and data should also
reflect the needs and priorities of the
patients
– Research information should go back
to patients in form of regular
newsletters and updates
– Effort should be made to ensure that
registries are global, not national /
allow international linkage of national
registries
– Researchers and companies that make
use of data from registries and
biobanks should make the generated
outcomes available to the community,
even if a project is discontinued and
results are not published.
– Patients organisations should be
represented in ethic committees; the
representatives should be multiple and
not always the same individuals
Clinical trials – Patient organisations should
take a leading role in ensuring
that (several) patients are
empowered for a competent
collaboration in this effort and
that they bring in the
community’s and not individual
concerns, for instance by
promoting Eurordis patients
expert courses (Eurordis’ Open
Academy)
– The consent form should be
elaborated in collaboration with
patient organisations
– Patient engagement should happen
from the very first phases of trial
planning and through the discussion
on design options (inclusion and




– The scientific rationale and rigor of the
trial should be in any case guaranteed;
clinical studies leaders should be
responsible of explaining such
rationales
– If children are the study participants,
their perspective and direct
engagement in decisions should be
addressed as with adult patients.
Consider possibility of diverging
opinions/priorities between patients
and their carers
– Clinical studies leaders are also
responsible for reporting study results
back to patients, even if negative, and
explain, in case, the reasons for study
discontinuation
– Part of the clinical trial budget and
allocated planning time should be
dedicated to the interaction with
patents and patient organisations,




– Prepare patients to understand
the specific situation of the trial
with its regulatory issues
– Consider conflict of interests
– Ensure that patients are aware of their
role in the consultation: as individual
patient or as representing of a patient
group
– Ensure that the participation of
disease-specific patients is guaranteed
also at the later phase of national
consultations for the reimbursement
and pricing
medicine is becoming increasingly actual, patient
representatives become more and more professional,
industry recognizes the high value of their contribu-
tion, and limitations of the reimbursement system of
health care makes a high patient compliance more
and more necessary.
George Padberg spanned the final bridge between
the traditional SDM in the bilateral patient-doctor
consultation to the broader range of professional
activities around NMD, where a patient involve-
ment at a higher level is not yet accomplished, or
not yet at equal levels in different European coun-
tries. The paternalistic approach of an old-fashioned
relationship between patient and professional is now
developing into the mutual trust, responsibility and
agreement, which is at the basis of SDM. The exten-
sion of the classical patient-physician-partnership to
a patient-professional-partnership that covers a broad
range of research aspects (like clinical trial readiness
and implementation, registries and biobanks) is not
only an ethical imperative but would serve the com-
munity and allow for faster progress. For instance,
inventory and prioritization of patient preferences
in the context of a clinical trial outcomes’ selec-
tion change over time and across cultures [18, 19]
and influence the trial design, and inclusion/exclusion
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Fig. 1. Levels of proactive patient involvement along the participation ladder (A. Ambrosini; modified from [17]).
criteria and recruitment strategies may benefit from
the patient perspective. Modern medicine faces new
challenges: for instance, gene therapy promises a final
cure but actually creates new phenotypes with pos-
sible new issues; personal and precision medicine is
not safe from side effects; preventive medicine does
not account for environmental factors. Therefore,
therapies require permanent medical supervision and
patients should take a lead in the discussion about
when to treat, when to stop, whom to treat, and whom
not. The described patient-professional-partnership
outside the dual interaction in the doctor’s room
requires that patients and doctors are organized in
networks and can work together under umbrella
organisations: the creation of a European Neuromus-
cular Trial Coordination Centre is suggested as a
possible solution.
TOPICS 1, 2 AND 3: SDM AND PATIENT
INVOLVEMENT IN QUALITY OF LIFE –
RELATED NMD RESEARCH
In general, quality of life (QoL) is the individ-
ual perception of the quality of daily life, including
all its emotional, social, and physical aspects. In
health care, health-related quality of life (HRQoL)
concerns the impact that a disease, disability or disor-
der may have on the individual’s well-being. Session
1 addressed HRQoL in NMD for topics related to
ethical and psychological burden of people affected
by neuromuscular conditions and their families at
the point of diagnosis and for screening promotion,
during transition to adulthood and throughout life,
with special focus on the various European countries’
conditions. The SDM and ladder of participation
models were adopted to investigate the quality of
information received and the level of involvement as
individuals and/or representatives of patient organi-
sations with emphasis on patients’ contribution in the
definition of research priorities.
Overall, the conclusions of this first session activity
indicated that more/better quality dialogue between
doctors and their patients is required. On the one
side, this is essential to help families coping with
the difficult moments of the diagnosis and adopt-
ing the best medical options and attitudes tailored
to their needs. On the other side, involving people
with a neuromuscular condition in clinical research
on HRQoL is fundamental to address what really
matters patients and incorporate their suggestions in
trial design. Moreover, patient organisations may play
a relevant role in creating awareness and engaging
professionals and public to stimulate discussion on
HRQoL topics at different societal level.
TOPIC 4: PATIENT INVOLVEMENT IN
REGISTRIES AND BIOBANKS
Hanns Lochmüller illustrated how rare disease
patients represent a paradigm for personalized
medicine and cutting-edge therapeutic developments,
since 70% of the diseases are monogenetic allow-
ing more straightforward approaches to understand
pathology and therapy targets, unlike more common
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diseases that are often etiologically complex. Today,
many rare disease research centres address the whole
translational pathway, from gene identification to
proof-of-concept studies, from the clinical trials and
natural history studies to back-translation of clini-
cal results into mechanism understanding, and from
research outcomes to therapy delivery. In this view,
rare disease research centres offer an ideal setup
to implement and integrate patient involvement at
all levels. The International Rare Diseases Research
Consortium (IRDiRC), launched in 2010, aims at
supporting and accelerating the development of ther-
apies for rare diseases, and despite having reached
some of its milestones ahead of time, the work to
be done remains huge [20]. Many areas of research
are overlapping across diseases and could be re-
used instead of re-invented, and many bottlenecks
are reconducible to lack of data sharing opportuni-
ties. Several initiatives aim at bridging such gaps
by offering the possibility to share more data and
tools, in particular through sample biobanks and dis-
ease registries [21, 22]. One good example of patient
co-creation in research program is the launching
of patient-driven, professionally supported disease
registries, like the UK myotonic dystrophy registry,
where the patient initiates the registration and names
a doctor that enters the clinical data. Criticized in
the past for the risk of bias and of gaps in the
data, such registries actually delivered the basis for
risk stratification and drug evaluation studies and
allowed, with large cohorts of well characterized
patients, for a faster clinical trial readiness in a
number of clinical trials and studies that followed
(20-24). Based on the same principle of shared
governance between clinicians and patient organ-
isations, the TREAT-NMD global registries have
been recognized by the IRDiRC as a valuable and
important resource [23–27]. Another good exam-
ple is the International Charter of principles for
sharing bio-specimens and data, developed in col-
laboration with patient representatives and meant
to offer a tool to overcome contradictory legal and
ethical frameworks across national borders that obsta-
cle effective sharing [28]. In general, despite not
systematically applied, patient involvement led to
positive results when integrated in research efforts.
There are many opportunities to explore an increased
level of patient involvement in the following issues:
setting goals, acquiring, providing and allocating
resources; distributing information; recruiting partic-
ipants; providing access; oversight and governance;
lobbying.
Panel Discussion: A model for patient
involvement in registries and biobanks
Major activities of a registry that applies SDM are
the incorporation of caregivers’ and patient involve-
ment from the beginning and the setting of research
priorities for registry-facilitated projects. This offers
a chance to engage people of different ages and
environments and identify their needs and their
expectations from the registry and from research
and educational efforts. Multi-stakeholder advisory
committees, online asynchronous focus groups and
surveys are useful tools to understand why people
prioritize certain types of research. It is important
to have a range of stakeholders participate in deci-
sion making, and to have the right plans, means and
personnel for dissemination. At the same time, it
should be avoided having always the same individuals
involved in all projects and committees. Patient com-
mitment is facilitated when registries and researchers
commit to reporting research results back to the data
providers, the patients and families. A challenge is
educating scientists to be flexible and change their
research protocols according to the priorities of the
research participants. For registries that obtain longi-
tudinal self-report data, updating of registry data can
become an issue. One strategy to motivate patients
and families to update their data is a closer exchange
of information – in this way supporting data shar-
ing instead of only data delivery, and further using
the data collected to develop educational materials.
Information can be presented in multiple formats to
enhance access by Registrants with different infor-
mation needs, as videos or infographics. Mike Snape
(AMO Pharma) illustrated his positive experience
with an early interaction with registries and individ-
ual patients, especially in identifying patient-relevant
outcome measures for clinical trials. He also encoun-
tered a conflict of interests between family- and
carer-priorities and patient priorities that, especially
in case of diseases with cognitive involvement, often
drive decisions away from the patient’s interest. In
other cases, excessive information is not wished by
the trial participant, and this needs to be respected. It
was noted that one main goal worth following by the
registries would be developing pressure on regulators
to create global registries for a real support to drug
development.
Similarly to registries, biobanks offer to
researchers the opportunity to share rare sam-
ples and to patients the opportunity of participating
in research. Challenges are the long times between
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donating a sample and learning what research
discovered out of it. The different levels of regula-
tions over the years and decades sometimes make
samples unusable for certain research projects,
simply because certain uses of samples (for instance
creating induced pluripotent cell lines) was not yet
known at the time of the written consent to use the
specimen. The distribution of cells duplicated or
cloned from the cell of a specific person needs to be
regulated. The information back to a donor whose
cells were genotyped and may reveal new risks or
opportunities for that particular person is not yet
structured. Similarly, the question arose about what
to do with data generated from biobank samples
during a research project, how long can they be
considered property of the researcher/company and
when should they be given back to the database.
Especially in the case a project is stopped and not
further developed, data generated should go back
to the biobank. Publications of research on biobank
samples should also be notified to the biobank, and
effort should be invested by biobanks in making use
of the samples and generate knowledge out of them.
Another issue is the understanding of the content
and consequences of written consents: patient
organisations should be involved in formulating the
consent forms in lay language. Ideally, they would
also support patients on their journey through the
research project to fully comprehend agreements.
To ensure the involvement of patients in deciding
how to overcome such problems, it is key to have a
powerful and balanced patient representation also in
ethics committees. In some cases, it may be useful
to have separate committees for professionals and
lay people, but the integration of knowledge from
both parts is critical. Also, it should be defined under
which circumstances a decision is considered shared
(majority, complete consensus, other models), and
at which level of the decision the consultation of all
stakeholders is actually introduced.
The common consensus of this group was that there
is definitely room for improved patient participation
in registries and biobanks. The conclusions can be
summarized into four main points: i) the patient’s
consent and its consequences for research upon enter-
ing in a registry or donation to a biobank needs to be
fully understood and improved; ii) the patients con-
sider themselves as owners of their data and samples,
therefore they should be appropriately represented in
any decision making or ethics committee that advises
or governs data usage; iii) information generated from
registries and biobanks should primarily benefit the
patient community either directly or indirectly, any
other usage of these services needs to be well jus-
tified and agreed; iv) information should go back to
patients in forms of newsletters and updates (see also
Table 1).
TOPIC 5: PATIENT INVOLVEMENT IN
CLINICAL TRIAL DESIGN
Baziel van Engelen presented his experience with
patient participation in the clinical trial OPTIMISTIC
(Observational Prolonged Trial In Myotonic Dystro-
phy type 1 to Improve Quality of Life Standards, a
Target Identification Collaboration). The trial was set
up to improve participation and activity and at the
same time to create a “trial toolbox” to facilitate future
trials: setting up clinical infrastructure for myotonic
dystrophy trials, validating outcome measures in a
time frame comparable to drug trials and identifying
individual or composite biomarker profiles. In many
aspects, the trial was designed similarly to a drug
trial: comparable time frame, use of similar outcome
measures (patient-reported and examiner-reported),
application of lessons learnt from pilot studies, care-
fully checking for side effects, molecular signature
of the treatment effect.
However, the planning of the trial did not fol-
low the classical way from preclinical animal data to
selection of patient outcome and clinical trial readi-
ness, instead, it followed the “reversed engineering”
approach: from the determinant of the health status
of DM1 patients through changing the determinants
by cognitive behavioural therapy, the selection of
appropriate biomarker to the identification of a drug-
gable target. From the beginning, patient involvement
was key in identifying the determinants of health
status, and hence the clinical trial design where
every participant selected the determinants he/she
wanted to change. The trial chose the cognitive
behavioural therapy as a tool to improve initiative and
physical activity; primary and secondary outcome
measures were defined based on patient preferences
but assessed with measurable scales. A question-
naire distributed to participants at the end of the trial
revealed that many of them had been motivated to
engage in the trial because of the extra time spent with
doctors and because of the wish to help researchers
in their work. The holistic approach therefore con-
tributed greatly to the retention of the patients in the
trial and the overall success of the trial, as compared
to the standard molecular approach. The concept of
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EQUALITY EQUITY
Fig. 2. Equal resources vs equal chances (from: http://muslimgirl.com/46703/heres-care-equity-equality/).
promoting health (vs decreasing the disease) and
treating the patient (vs treating the disease) led in this
case to an impressive retention level throughout the
study and to a very high satisfaction of the involved
patients. Van Engelen underlined the importance for
the neurologist to understand the concepts of recovery
approach and capability when dealing with SDM. The
recovery approach is the support of a person’s poten-
tial for recovery, where recovery is generally seen as a
personal journey rather than a goal to be reached. The
“capability”, a concept borrowed from the economic
sciences, is the real opportunity to be and do what
one has reason to value (‘potential achievements’)
and depends on the real freedom in the assessment of
a person’s advantage and on the availability of equity,
i.e. equal chances instead of equal resources: equal
resources do not necessarily imply the equal chance
to use these resources [29] (Fig. 2).
Discussion: A model for patient involvement in
clinical trial design
Having the patient voice in a clinical trial is not
only feasible, it should be a logical and natural thing.
The quality of consultation between professionals
and patients was addressed, highlighting that the per-
ception of a good consultation may vary between the
two parties. The involvement of persons with a NMD
(or patients organisations) in clinical trials, as expert
of the own disease, should happen in a proactive way
from the beginning and through the discussion on
trial design options. Not only on patient reported out-
come measures (PROMS) the patient voice should be
included. In other words, the final goal of the patient’s
co-creation in clinical trials is to set up a sustainable
patient-professionals-partnership with a clear com-
munication strategy, expectations’ management and
results sharing.
Patient organisations should be responsible to iden-
tify patients for the co-creation of a clinical trial
design, to empower them with the necessary back-
ground information needed to fulfil this role, and
to make sure that the involved patients bring in
the community’s concerns and not only the own
ones. This should be taken into consideration also
with patients of young age. It is important also to
balance the patient legitimate wishes and opinions
with the scientific rationale; the responsibility of the
researchers is to explain this rationale and if neces-
sary explain why a certain study cannot be done, and
to report back to patients the results of a study, even if
negative.
Ideally, patients should be contacted before setting
up the research plan of a clinical trial, be involved
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in all main phases (trial design, inclusion/exclusion
criteria definition, outcomes definition, recruitment
and preparation of the informed consent). Part of the
budget should be devoted to this collaboration.
The conclusion of the group can be summarized
in three points: i) patient participation in clinical
trial design is desirable from the very first phases
of trial design at the level of co-creation (partner-
ship) and a dedicated budget should be reserved
for this interaction by the clinical trial sponsors/PIs;
ii) patient organisations should play an active role
in identifying and promoting proactive individuals
and in giving the necessary information and knowl-
edge to fill their role in clinical trial design; iii)
researchers should be responsible in sharing results
(also if negative) with patients after the trial (see also
Table 1).
TOPIC 6: PATIENT INVOLVEMENT IN
THE REGULATORY AND CONSENTING
PROCESSES
Patient preferences and priorities can be included
in all steps of drug development, from upstream
research to the post-approval phase (see for instance
DIA Consideration Guide [30] and EMA lifecycle
opportunities [31]. Today, several companies wish
to assess patient preferences for their clinical trials
and run patient preference studies. However, there is
little consensus on the methodology to assess such
preferences, on the design of such studies and even
on the definition and role of patient preferences.
Mats Hansson led this section and presented his
experience as coordinator of the ongoing study PRE-
FER, a 5-years public-private collaborative research
project under the Innovative Medicines Initiative
(IMI) that received contributions from the Horizon
2020 programme and from the European Federa-
tion of Pharmaceutical Industries and Associations.
The PREFER project aims at identifying methods for
preference elicitation, education and psychological
measures in the literature, considering a set of criteria
to determine which methods are suitable at different
decision points in the drug life cycle. It addresses
three main questions: What matters to patients? How
much does it matter? What matters most? Answers
to these questions depend greatly on the background
information received by patients, but also on their
condition and age. With the candidate methodologies
and assessment criteria, patient preference studies
will be run in three disease areas where patients and
clinical research partners have been engaged: can-
cer, rheumatoid arthritis and NMD. These studies will
evaluate at different decision points in the drug devel-
opment process what patients deem relevant about
their disease, which treatment options they prefer and
their willingness to accept trade-offs between bene-
fits and risks of their treatment. Finally, the project
aims at developing evidence-based recommendations
and best practices for conducting clinical case studies
that offer industry, Regulatory Authorities and HTA
bodies a valuable support in decision making.
Discussion: A model for patient involvement in
regulatory and consenting processes
Participants in this working group discussed their
experience of interaction with the Regulatory Author-
ities, and, in particular, with European Medicines
Agency (EMA). Direct contacts occur at differ-
ent stages of the development of medicines, from
design of trial protocols, including patient related
outcome measures, to pre-approval, evaluation and
post-approval phases, and involve both profession-
als and patient representatives. All agreed that EMA
has always been very open and proactive in listening
to the different voices, with the aim of understand-
ing both the clinical background of a disease and the
burden that it puts on the daily life of patients, fami-
lies, and caregivers. Experiences include involvement
in discussions on risk-benefits analyses within the
assessment of marketing authorisation applications
for new therapeutics. Patient representatives found
this experience extremely valuable, although very
demanding, as they take important responsibilities
towards their community. Particularly, the following
challenges were identified: i) need for an understand-
ing of the specific situation (disease natural history,
drug efficacy and safety etc.), which implies that the
patient has to be prepared to read some background
information in relation to the clinical and regulatory
issues; ii) independence from companies that have
developed the product (if any), to avoid any conflict
of interest; iii) if possible, good level of connec-
tion with the larger patient community, to also be
able to share some wider perspectives, but this is not
necessarily a requirement (depends on the particular
activity), as there is always an intrinsic value even for
individual patients to bring their own real life perspec-
tives. Therefore, a right blend of “naı̈veté” (meant
as original view of patient’s perspective) and some
knowledge of the regulatory dynamics is considered
optimal.
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EMA relies very much on European patient organ-
isations, such as EURORDIS and condition-specific
patient organisations to identify the most suitable
patient representatives, in addition to its own patient
database (where individual patients can register).
There are several initiatives in place to help achieve
relevant competences such as the EURORDIS sum-
mer schools and EUPATI trainings, to support
patients who want to take this challenge. Another area
where patient involvement is required concerns the
interaction with HTA bodies, where development and
selection of HTA endpoints and the economic eval-
uation are yet to be defined. For instance, patients’
preferences in ease of use of device, ease of use of
drug administration, caregivers burden should be con-
sidered. Issues concerning costs of healthcare derived
from longer living and how this affects HTA should
be discussed separately in ethics committees. It was
noted that representatives of patient view in national
ethics committees for rare diseases are rarely directly
expert patients. A fair representation of patient pref-
erences at both regulatory agencies and HTA bodies
can be achieved by surveys. To this regard, the con-
sensus of this group was that: i) methodologically
well-planned surveys on patient preferences on the
risk-benefit assessment and on the economical eval-
uation of a new medicine should be conducted with
transparent processes, instruments, analysis and pub-
lication of results; ii) results of such surveys should
flow into educational programs for expert patients;
iii) expert patients or patient representatives should
also be included in national ethics committees (see
also Table 1).
The working group also encouraged a direct patient
participation in the process of definition of the
Informed Consent. As already noted in the context
of consent forms for registries, biobanks, and clini-
cal trials, these are often not easily understandable or
too long. In case of a clinical trial, informed con-
sent forms need to frame the expectations on the
trial and provide realistic information. All agreed that
the involvement of patients in the trial set-up and in
the formulation of the consent form would be useful
to increase readability and compliance/commitment.
The information for generating the consent should
also state clearly that a feedback on the study out-
comes would be provided to all participants at the
end of the trial. Also, the amendments during the
trial should be re-discussed with the patients. Another
important issue raised concerned children’s partici-
pation in the trials. Consent forms for children do
exist but a major effort should be put in making sure
that the consent also capture the effective child’s
preferences, with respect to those of the parents.
An additional observation was made in relation to
“access to new medicines” which is an area bridg-
ing over from clinical research to health care. Across
Europe, there is a single regulatory body (EMA)
in charge of marketing authorization, but multiple
national bodies in charge of reimbursement and pric-
ing which determines whether patients receive such
new medications. It was stressed that patients and
patient organisations need to be fully involved in such
consultation process.
CONCLUSIONS
With this workshop, ENMC aimed at looking at the
position of patients with neuromuscular conditions in
the decision processes regarding research and drug
development. Considerable progress has been made
in the last decades that resulted in a higher involve-
ment of patients and patient organisations in clinical
development. Several examples presented during the
workshop showed that partnership and co-creation
between professionals of neuromuscular disease and
the patients – the real experts of the diseases –
improve collaboration, compliance, and commitment
on both sides. On the long term, this improves gener-
ation of positive research results and progress toward
effective treatments and standards of care. However,
the workshop identified some areas of research that
need improvement and developed the recommenda-
tions summarized in Table 1. We identified three types
of improvements, for which different stakeholders
are in charge: i) Educational changes, to be imple-
mented by patients organisations and institutions,
comprise those changes needed to develop a better
understanding of processes to allow for a full and
competent patients involvement; ii) Cultural changes,
to be implemented by all stakeholders, are those
changes of basic societal attitudes that will facilitate
the implementation of a higher patients involvement;
iii) Structural changes, to be implemented by profes-
sional stakeholders, are changes in the work flow that
will make space for an increased patient participation.
With this report, ENMC wishes to contribute to the
world-wide effort to improve patient position on the
ladder of participation, with a particular focus on the
gaps and needs of the neuromuscular community and
hopes to offer a practical tool to implement awareness
and discussions on the necessary changes.
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